<DOC>
	<DOCNO>NCT01473602</DOCNO>
	<brief_summary>The purpose study see whether teriparatide , give 6 month versus placebo , improve heal hip ( femoral neck ) fracture repair surgery use certain type orthopedic screw . The study enroll men postmenopausal woman least 50 year age recent hip ( femoral neck ) fracture cause low-trauma ( example , fall stand height less ) .</brief_summary>
	<brief_title>Second Study Effect Teriparatide Hip Fracture Healing</brief_title>
	<detailed_description>This 12-month , Phase 3 , prospective , randomize , parallel , double-blind , placebo-controlled , multicenter , multinational study evaluate effect 6 month treatment teriparatide fracture heal participant sustain recent low-trauma , unilateral , femoral neck fracture stabilize internal fixation . The study 3 period : 1 . A screening period must complete ≤ 14 day operative treatment femoral neck fracture 2 . A 6-month double-blind treatment period [ teriparatide 20 ( µg ) placebo give daily subcutaneous injection ] 3 . A 6-month observation period . The primary objective ass effect 6 month treatment teriparatide 20 µg/day versus placebo proportion men postmenopausal woman least 50 year age revision surgery 12 month internal fixation low-trauma femoral neck fracture . All participant receive supplement calcium vitamin D begin screen continue 12 month .</detailed_description>
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Femoral Neck Fractures</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Community dwell men postmenopausal woman ambulatory sustain lowtrauma , unilateral femoral neck fracture ( displace nondisplaced ) Other femoral neck fracture , free incapacitating condition life expectancy least 2 year Have receive eligible treatment internal fixation ( slide hip screw multiple cancellous screw ) femoral neck fracture ( surgical procedure perform part study ) Have give write informed consent ( participant proxy ) inform risk , medication , study procedure Increased baseline risk osteosarcoma History unresolved skeletal disease affect bone metabolism primary osteoporosis Abnormally elevate serum calcium screen Abnormally elevate serum intact parathyroid hormone ( PTH ) ( 184 ) screening Severe vitamin D deficiency screen Active liver disease jaundice Significantly impair renal function Abnormal thyroid function correct therapy History malignant neoplasm 5 year prior screen History bone marrow solid organ transplantation History symptomatic nephrolithiasis urolithiasis 1 year prior screen Previous treatment follow bone active drug allow must discontinue screening : oral bisphosphonates , selective estrogen receptor modulators ( SERMs ) , calcitonin , estrogen ( oral , transdermal , injectable ) , progestin , estrogen analog , estrogen agonist , estrogen antagonist tibolone , active vitamin D3 analog . Androgen anabolic steroid use must discontinue , except use physiologic replacement testosterone Previous treatment follow bone active drug exclusionary , state treatment duration meet : strontium ranelate duration , intravenous bisphosphonates 12 month precede screening , and/or denosumab 6 month precede screen Prior treatment PTH , teriparatide , PTH analog , prior participation clinical trial study PTH , teriparatide , PTH analogs Local systemic treatment bone morphogenic proteins growth factor Previous fracture ( ) bone surgery currently fracture hip Softtissue infection operation site Treatment bone graft osteotomy Treatment augmentation use type degradable cement , hydroxyapatitecoated implant , noninvasive intervention Associated major injury low extremity include fracture foot , ankle , tibia , fibula , knee , femur , femoral head , pelvis ; dislocation ankle , knee , hip</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>